Brexanolone - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for brexanolone and what is the scope of patent protection?
Brexanolone
is the generic ingredient in one branded drug marketed by Sage Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Brexanolone has one hundred and twenty-three patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for brexanolone
International Patents: | 123 |
US Patents: | 8 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 56 |
Clinical Trials: | 11 |
Patent Applications: | 1,004 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for brexanolone |
What excipients (inactive ingredients) are in brexanolone? | brexanolone excipients list |
DailyMed Link: | brexanolone at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brexanolone
Generic Entry Date for brexanolone*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for brexanolone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Brii Biosciences Limited | Phase 1 |
Sage Therapeutics | Phase 2 |
Brigham and Women's Hospital | Phase 4 |
Pharmacology for brexanolone
Drug Class | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator |
Mechanism of Action | GABA A Receptor Positive Modulators |
Anatomical Therapeutic Chemical (ATC) Classes for brexanolone
US Patents and Regulatory Information for brexanolone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for brexanolone
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 276403 | תכשירים פרמצבטיים הכוללים אלופרגננולון (Pharmaceutical compositions comprising allopregnanolone) | ⤷ Sign Up |
European Patent Office | 4295908 | FORMULATIONS STÉROÏDIENNES NEUROACTIVES COMPRENANT UN COMPLEXE D'ALLOPRÉGNANOLONE ET D'ÉTHER SULFOBUTYLIQUE BÊTA-CYCLODEXTRINE (NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN) | ⤷ Sign Up |
New Zealand | 773177 | Neuroactive steroid formulations and methods of treating cns disorders | ⤷ Sign Up |
Taiwan | I798173 | ⤷ Sign Up | |
China | 114053423 | 磺烷基醚环糊精组合物 (Sulfoalkyl ether cyclodextrin compositions) | ⤷ Sign Up |
Australia | 2017229656 | Neuroactive steroids, compositions, and uses thereof | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.